Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Respiratory Tract Neoplasms HELP
Based on 96,673 articles published since 2010
|||| 83 

These are the 96673 published articles about Respiratory Tract Neoplasms that originated from Worldwide during 2010-2020.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Advanced non-small cell lung cancer - Treatment with Pembrolizumab. 2019

Silvinato, Antonio / Floriano, Idevaldo / Bernardo, Wanderley Marques. ·. Associação Médica Brasileira, São Paulo, SP, Brasil. · . Coordenador do Programa Diretrizes da Associação Médica Brasileira, São Paulo, SP, Brasil E-mail: wmbernardo@usp.br. ·Rev Assoc Med Bras (1992) · Pubmed #31994619.

ABSTRACT: -- No abstract --

2 Guideline [How I manage... Malignant pleural mesothelioma in 2019]. 2019

Pellegrini, I / Sibille, A / Paulus, A / Vaillant, F / Radermecker, M A / Corhay, J L / Louis, R / Duysinx, B. ·Service de Pneumologie, CHU Liège, Belgique. · Service de Chirurgie cardiovasculaire, CHU Liège, Belgique. · Service de Pneumologie, CHU Liège, Belgique.. ·Rev Med Liege · Pubmed #31833271.

ABSTRACT: Malignant pleural mesothelioma is a rare disease originating from mesothelial cells of the pleura and is related to asbestos exposure. The tumor is generally extended at the time of diagnosis and the treatment consists of a systemic palliative therapy. Radical approach is limited to very selected patients and is performed in expert centers but without validated schema. Radiotherapy alone is mainly used in palliative intent. Platinum-based chemotherapy in association with pemetrexed is the frontline standard of care and provides a 12-month overall survival. The addition of bevacizumab, an antiangiogenic drug, shows an improvement in median survival. To date, there is no second-line treatment approved for this disease and therefore inclusion in trials is recommended. Currently, various studies are investigating target therapy, immunotherapy and intrapleural perioperative treatment.

3 Guideline A Radiologist's Guide to the Changing Treatment Paradigm of Advanced Non-Small Cell Lung Cancer: The ASCO 2018 Molecular Testing Guidelines and Targeted Therapies. 2019

Chen, Lydia / Smith, Daniel A / Somarouthu, Bhanusupriya / Gupta, Amit / Gilani, Kianoush Ansari / Ramaiya, Nikhil H. ·Department of Radiology, University Hospitals Cleveland Medical Center, 11100 Euclid Ave, Cleveland, OH 44106. · Department of Radiology, Harvard Medical School, Massachusetts General Hospital, Boston, MA. ·AJR Am J Roentgenol · Pubmed #31361530.

ABSTRACT:

4 Guideline National Clinical Practice Guidelines for the management of non-small cell lung cancer in early, locally advanced and metastatic stages. Extended version. 2019

Barrón-Barrón, Feliciano / Guzmán-De Alba, Enrique / Alatorre-Alexander, Jorge / Aldaco-Sarvider, Fernando / Bautista-Aragón, Yolanda / Blake-Cerda, Mónica / Blanco-Vázquez, Yazmín Carolina / Campos-Gómez, Saúl / Corona-Cruz, José Francisco / Iñiguez-García, Marco Antonio / Lozano-Ruiz, Francisco Javier / Maldonado-Magos, Federico / de la Mata-Moya, Dolores / Martínez-Barrera, Luis Manuel / Ramos-Prudencio, Rubí / Rodríguez-Cid, Jerónimo / Rivera-Rivera, Samuel / Trejo-Rosales, Raúl Rogelio / Aguilar-Ortíz, Marco Rodrigo / Astudillo-de la Vega, Horacio / Barajas-Figueroa, Luis Javier / Barroso-Quiroga, Nimbe / Blanco-Salazar, Andrés / Castillo-Ortega, Graciano / Domínguez-Parra, Luis Manuel / Enriquez-Aceves, María Isabel / Fernández-Orozco, Armando / Figueroa-Morales, Marco Antonio / Green-Schneewiss, León / González-Garay, Jorge Alejandro / González Ramírez-Benfield, Rogelio / Guadarrama-Orozco, Alberto / Guerrero-Ixtlahuac, Jorge / Hernández-Barajas, David / Hernández-Montes de Oca, Raymundo / Kelly-García, Javier / Lázaro-León, Miguel / Silva-Bravo, Fernando / Tellez-Becerra, Jóse Luis / Macedo-Pérez, Eleazar Omar / Maza-Ramos, Gibert / Mayorga-Butrón, José Luis / Montaño-Velázquez, Bertha Beatriz / Murillo-Medina, Karina / Narváez-Fernández, Salvador / Ochoa-Carrillo, Francisco Javier / Olivares-Beltrán, Guillermo / Olivares-Torres, Carlos / Ponce de León-Castillo, Mario / Ponce-Viveros, Mario Alberto / Rubio-Gutiérrez, Jaime Ernesto / Sáenz-Frías, Julia Angelina / Silva-Vivas, Jorge Alberto / Santillán-Doherty, Patricio / Soto-Ávila, Juan José / Toledo-Buenrostro, Vinicio / Vargas-Abrego, Benito / Velasco-Hidalgo, Liliana / Zapata-Tarres, Marta Margarita / Quintero-Beuló, Gregorio / Arrieta, Oscar. ·Instituto Nacional de Cancerología. Ciudad de México, México. · Instituto Nacional de Enfermedades Respiratorias. Ciudad de México, México. · Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Ciudad de México, México. · Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social. Ciudad de México, México. · Centro de Cáncer ABC, Centro Médico ABC. Ciudad de México, México. · Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios. Estado de México, México. · Centro Oncológico Medica Sur. Ciudad de México, México. · Instituto Nacional de Ciencias Médicas y de la Nutrición Dr. Salvador Zubirán, SSA. Ciudad de México, México. · Steering Comitee, Guidelines International Network North America. New York, USA. · Grupo Ángeles. Ciudad de México, México. · Hospital Universitario Dr. Angel Leaño. Zapopan, Jalisco, México. · Instituto Mexicano del Seguro Social. Guanajuato, México. · Star Médica. Baja California, México. · Centro Médico del Noreste, UMA 25, Instituto Mexicano del Seguro Social. Nuevo León, México. · Hospital Civil de Guadalajara. Jalisco, México. · Hospital General del Estado. Sonora, México. · Instituto Jaliciense de Cancerología. Guadalajara, Jalisco. · Hospital General de México Dr. Eduardo Liceaga. Ciudad de México, México. · Instituto Mexicano del Seguro Social. Puebla, México. · Programa de Maestría y Doctorado en Ciencias Médicas, Unidad de Posgrado, Facultad de Medicina, UNAM. Ciudad de México, México. · Instituto Nacional de Pediatría, Ciudad de México, México. · Hospital Regional General Zaragoza, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado. Ciudad de México, México. ·Salud Publica Mex · Pubmed #31276353.

ABSTRACT: OBJECTIVE: Lung cancer is one the leading causes of mortality worldwide. Symptomatic manifestations of the disease generally occur in the advanced-stage setting, and therefore an important number of patients have advanced or metastatic disease by the time they are diagnosed. This situation contributes to a poor prognosis in the treatment of lung cancer. Evidencebased clinical recommendations are of great value to support decision-making for daily practice, and thus improving health care quality and patient outcomes. MATERIALS AND METHODS: This document was an initiative of the Mexican Society of Oncology (SMEO) in collaboration with Mexican Center of Clinical Excellence (Cenetec) according to Interna- tional Standards. Such standards included those described by the IOM, NICE, SIGN and GI-N. An interdisciplinary Guideline Development Group (GDG) was put together which included medical oncologists, surgical oncologistsc, radiation therapists, and methodologists with expertise in critical appraisal, sys- tematic reviews and clinical practice guidelines development. RESULTS: 62 clinical questions were agreed among members of the GDG. With the evidence identified from systematic reviews, the GDG developed clinical recommendations using a Modified Delphi Panel technique. Patients' representatives validated them. CONCLUSIONS: These Clinical Practice Guideline aims to support the shared decision-making process for patients with different stages of non-small cell lung cancer. Our goal is to improve health-care quality on these patients.

5 Guideline Multidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastases. 2019

Ponce, Santiago / Bruna, Jordi / Juan, Oscar / López, Rafael / Navarro, Alejandro / Ortega, Ana Laura / Puente, Javier / Verger, Eugènia / Bartolomé, Adela / Nadal, Ernest. ·Lung Cancer Clinical Research Unit, Hospital Universitario 12 de Octubre, Av. Cordoba, s/n, 28041 Madrid, Spain. Electronic address: sponceaix@gmail.com. · Neuro-Oncology Unit, Bellvitge University Hospital-ICO, Carrer de la Feixa Llarga, s/n, 08907, L'Hospitalet de Llobregat, Barcelona, Spain; Clinical Research in Solid Tumors (CReST) and Neuro-Oncology Group. Oncobell, IDIBELL, Avda Gran Via 199-203, 08907, L'Hospitalet de Llobregat, Barcelona, Spain. Electronic address: jbruna@bellvitgehospital.cat. · Medical Oncology Service, Hospital Universitario y Politécnico La Fe, Valencia, Avda. de Fernando Abril Martorell, nº 106, 46026, Valencia, Spain. Electronic address: juan_osc@gva.es. · Medical Oncology Unit. Hospital Clínico Universitario de Valladolid, Av. Ramón y Cajal, 3, 47003, Valladolid, Spain. Electronic address: rafalopezcastro@yahoo.es. · Medical Oncology. Hospital Vall d'Hebron, Passeig de la Vall d'Hebron, 119-129, 08035, Barcelona, Spain. Electronic address: alexnavarro84@gmail.com. · Oncology Research Unit, Complejo Hospitalario de Jaén, Av. del Ejército Español, 10, 23007, Jaén, Spain. Electronic address: analauraortega@gmail.com. · GU, Thoracic and Melanoma Cancer Unit, Medical Oncology Department, Assistant Professor of Medicine, Complutense University. Hospital Clinico Universitario San Carlos, Calle del Prof Martín Lagos, s/n, 28040, Madrid, Spain. Electronic address: javierpuente.hcsc@gmail.com. · Radiation Oncology Department, Hospital Clínic de Barcelona, Carrer de Villarroel, 170, 08036, Barcelona, Spain. Electronic address: everger@clinic.cat. · Radiotherapy Oncology Department. Hospital Universitario 12 de Octubre, Av. Cordoba, s/n, 28041, Madrid, Spain. Electronic address: adelabartolome@gmail.com. · Clinical Research in Solid Tumors (CReST) and Neuro-Oncology Group. Oncobell, IDIBELL, Avda Gran Via 199-203, 08907, L'Hospitalet de Llobregat, Barcelona, Spain; Thoracic Oncology Unit, Department of Medical Oncology, Catalan Institute of Oncology. Avda Gran Via 199-203, 08907, L'Hospitalet de Llobregat, Barcelona, Spain. Electronic address: esnadal@iconcologia.net. ·Crit Rev Oncol Hematol · Pubmed #31092376.

ABSTRACT: The presence of an epidermal growth factor receptor (EGFR) mutation is associated with higher incidence of brain metastases in patients with non-small cell lung cancer (NSCLC); however, patients with synchronous brain metastases at diagnosis have generally been excluded from clinical trials. As there is limited clinical evidence for managing this patient population, a multidisciplinary group of Spanish medical and radiation oncologists, and neuro-oncologist with expertise treating brain metastases in lung cancer patients met with the aim of reaching and developing an expert opinion consensus on the management of patients with EGFR mutated NSCLC with brain metastases. This consensus contains 26 recommendations and 20 conclusion statements across 21 questions in 7 areas, as well as a first-line treatment algorithm.

6 Guideline The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. 2019

Akamatsu, Hiroaki / Ninomiya, Kiichiro / Kenmotsu, Hirotsugu / Morise, Masahiro / Daga, Haruko / Goto, Yasushi / Kozuki, Toshiyuki / Miura, Satoru / Sasaki, Takaaki / Tamiya, Akihiro / Teraoka, Shunsuke / Tsubata, Yukari / Yoshioka, Hiroshige / Hattori, Yoshihiro / Imamura, Chiyo K / Katsuya, Yuki / Matsui, Reiko / Minegishi, Yuji / Mizugaki, Hidenori / Nosaki, Kaname / Okuma, Yusuke / Sakamoto, Setsuko / Sone, Takashi / Tanaka, Kentaro / Umemura, Shigeki / Yamanaka, Takeharu / Amano, Shinsuke / Hasegawa, Kazuo / Morita, Satoshi / Nakajima, Kazuko / Maemondo, Makoto / Seto, Takashi / Yamamoto, Nobuyuki. ·Internal Medicine III, Wakayama Medical University, Wakayama, Japan. · Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. · Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. · Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Aichi, Japan. · Osaka City General Hospital, Osaka, Japan. · Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. · Clinical Research Center, Department of Thoracic Oncology and Medicine, National Hospital Organization Shikoku Cancer Center, Ehime, Japan. · Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan. · Respiratory Center, Asahikawa Medical University Hospital, Hokkaido, Japan. · National Hospital Organization Kinki-chuo Chest Medical Center, Osaka, Japan. · Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine, Shimane University Faculty of Medicine, Shimane, Japan. · Department of Thoracic Oncology, Kansai Medical University Hospital, Osaka, Japan. · Department of Thoracic Oncology, Hyogo Cancer Center, Hyogo, Japan. · Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan. · Department of Surgery, University of California San Diego, California, USA. · National Cancer Center Hospital East, Chiba, Japan. · Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan. · First Department of Medicine, Hokkaido University Hospital, Hokkaido, Japan. · Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan. · Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan. · Kyushu University Hospital, Fukuoka, Japan. · Regional Respiratory Symptomatology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. · Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. · Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan. · Department of Biostatistics, Yokohama City University School of Medicine, Kanagawa, Japan. · Japan Federation of Cancer Patient Groups, Tokyo, Japan. · Japan Lung Cancer Alliance, Tokyo, Japan. · Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan. · Shizuoka Cancer Center, Shizuoka, Japan. · Division of Pulmonary Medicine, Allergry and Rheumatology, Department of Internal Medicine, Iwate Medical University School of Medicine, Iwate, Japan. · Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan. setocruise@gmail.com. ·Int J Clin Oncol · Pubmed #31049758.

ABSTRACT: According to rapid development of chemotherapy in advanced non-small cell lung cancer (NSCLC), the Japan Lung Cancer Society has been updated its own guideline annually since 2010. In this latest version, all of the procedure was carried out in accordance with grading of recommendations assessment, development and evaluation (GRADE) system. It includes comprehensive literature search, systematic review, and determination of the recommendation by multidisciplinary expert panel which consisted of medical doctors, pharmacists, nurses, statisticians, and patients from patient advocacy group. Recently, we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors. Thus, the guideline proposes to categorize patients into three entities: (1) driver oncogene-positive, (2) PD-L1 ≥ 50%, and (3) others. Based on this subgroup, 31 clinical questions were described. We believe that this attempt enables clinicians to choose appropriate treatment easier. Here, we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC, stages IV.

7 Guideline The American Society of Clinical Oncology-endorsed American Society for Radiation Oncology Evidence-Based Guideline of stereotactic body radiotherapy for early-stage non-small cell lung cancer: An expert opinion. 2019

Guckenberger, Matthias / Aerts, Joachim G / Van Schil, Paul / Weder, Walter. ·Department for Radiation Oncology, University Hospital Zurich, University Zurich, Zurich, Switzerland. · Department of Pulmonary Diseases, Erasmus MC, Rotterdam, The Netherlands. · Department of Thoracic and Vascular Surgery, Antwerp University Hospital and Antwerp University, Antwerp, Belgium. · Department of Thoracic Surgery, University Hospital Zurich, University Zurich, Zurich, Switzerland. Electronic address: walter.weder@usz.ch. ·J Thorac Cardiovasc Surg · Pubmed #30557952.

ABSTRACT: -- No abstract --

8 Guideline [Chinese Medical Association guidelines for clinical diagnosis and treatment of lung cancer (Edition 2018)]. 2018

Anonymous3690974 / Anonymous3700974 / Anonymous3710974. · ·Zhonghua Zhong Liu Za Zhi · Pubmed #30605986.

ABSTRACT: -- No abstract --

9 Guideline ACR Appropriateness Criteria 2018

Anonymous7220967 / Donnelly, Edwin F / Kazerooni, Ella A / Lee, Elizabeth / Henry, Travis S / Boiselle, Phillip M / Crabtree, Traves D / Iannettoni, Mark D / Johnson, Geoffrey B / Laroia, Archana T / Maldonado, Fabien / Olsen, Kathryn M / Shim, Kyungran / Sirajuddin, Arlene / Wu, Carol C / Kanne, Jeffrey P. ·Panel Chair, Vanderbilt University Medical Center, Nashville, Tennessee. Electronic address: edwin.donnelly@vumc.org. · University of Michigan Medical Center, Ann Arbor, Michigan. · Research Author, University of Michigan Health System, Ann Arbor, Michigan. · Panel Vice-Chair, University of California San Francisco, San Francisco, California. · Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Florida. · Southern Illinois University School of Medicine, Springfield, Illinois; The Society of Thoracic Surgeons. · University of Iowa, Iowa City, Iowa; The Society of Thoracic Surgeons. · Mayo Clinic, Rochester, Minnesota. · University of Iowa Hospitals and Clinics, Iowa City, Iowa. · Vanderbilt University Medical Center, Nashville, Tennessee; American College of Chest Physicians. · Radiology Imaging Associates, Englewood, Colorado. · John H. Stroger Jr Hospital of Cook County, Chicago, Illinois; American College of Physicians. · National Institutes of Health, Bethesda, Maryland. · The University of Texas MD Anderson Cancer Center, Houston, Texas. · Specialty Chair, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. ·J Am Coll Radiol · Pubmed #30392603.

ABSTRACT: Lung cancer remains the leading cause of cancer death in both men and women. Smoking is the single greatest risk factor for the development of lung cancer. For patients between the age of 55 and 80 with 30 or more pack years smoking history who currently smoke or who have quit within the last 15 years should undergo lung cancer screening with low-dose CT. In patients who do not meet these criteria but who have additional risk factors for lung cancer, lung cancer screening with low-dose CT is controversial but may be appropriate. Imaging is not recommended for lung cancer screening of patient younger than 50 years of age or patients older than 80 years of age or patients of any age with less than 20 packs per year history of smoking and no additional risk factor (ie, radon exposure, occupational exposure, cancer history, family history of lung cancer, history of COPD, or history of pulmonary fibrosis). The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.

10 Guideline American Thoracic Society/American Lung Association Lung Cancer Screening Implementation Guide. 2018

Thomson, Carey C / Mckee, Andrea B. ·1 Department of Medicine Mount Auburn Hospital Cambridge, Massachusetts. · 2 Harvard Medical School Boston, Massachusetts. · 3 Division of Radiation Oncology Lahey Hospital & Medical Center Burlington, Massachusetts and. · 4 Tufts University School of Medicine Boston, Massachusetts. ·Am J Respir Crit Care Med · Pubmed #30382762.

ABSTRACT: -- No abstract --

11 Guideline NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018. 2018

Kalemkerian, Gregory P / Loo, Billy W / Akerley, Wallace / Attia, Albert / Bassetti, Michael / Boumber, Yanis / Decker, Roy / Dobelbower, M Chris / Dowlati, Afshin / Downey, Robert J / Florsheim, Charles / Ganti, Apar Kishor P / Grecula, John C / Gubens, Matthew A / Hann, Christine L / Hayman, James A / Heist, Rebecca Suk / Koczywas, Marianna / Merritt, Robert E / Mohindra, Nisha / Molina, Julian / Moran, Cesar A / Morgensztern, Daniel / Pokharel, Saraswati / Portnoy, David C / Rhodes, Deborah / Rusthoven, Chad / Sands, Jacob / Santana-Davila, Rafael / Williams, Charles C / Hoffmann, Karin G / Hughes, Miranda. · ·J Natl Compr Canc Netw · Pubmed #30323087.

ABSTRACT: The NCCN Guidelines for Small Cell Lung Cancer (SCLC) address all aspects of disease management. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for SCLC regarding immunotherapy, systemic therapy, and radiation therapy. For the 2018 update, new sections were added on "Signs and Symptoms of SCLC" and "Principles of Pathologic Review."

12 Guideline Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2018

Planchard, D / Popat, S / Kerr, K / Novello, S / Smit, E F / Faivre-Finn, C / Mok, T S / Reck, M / Van Schil, P E / Hellmann, M D / Peters, S / Anonymous831090. ·Department of Medical Oncology, Thoracic Group, Gustave-Roussy Villejuif, France. · Royal Marsden Hospital, London. · Aberdeen Royal Infirmary, Aberdeen University Medical School, Aberdeen, UK. · Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, Italy. · Thoracic Oncology Service, Netherlands Cancer Institute, Amsterdam, The Netherlands. · Division of Cancer Sciences, University of Manchester, Manchester, UK. · Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China. · LungenClinic Airway Research Center North (ARCN), German Center for Lung Research, Grosshansdorf, Germany. · Department of Thoracic and Vascular Surgery, Antwerp University Hospital and Antwerp University, Antwerp, Belgium. · Weill Cornell Medical College, New York, USA. · Medical Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. ·Ann Oncol · Pubmed #30285222.

ABSTRACT: -- No abstract --

13 Guideline Updated Fleischner Society Guidelines for Managing Incidental Pulmonary Nodules: Common Questions and Challenging Scenarios. 2018

Bueno, Juliana / Landeras, Luis / Chung, Jonathan H. ·From the Department of Radiology and Medical Imaging, University of Virginia Medical Center, 1215 Lee St, PO Box 800170, Charlottesville, VA 22908 (J.B.) · and Department of Radiology, University of Chicago, Chicago, Ill (L.L., J.H.C.). ·Radiographics · Pubmed #30207935.

ABSTRACT: The new guidelines for managing incidental pulmonary nodules published by the Fleischner Society in 2017 reflect an improved understanding of the risk factors and biologic features of lung cancer. Specific topics emphasized in the updated guidelines include a new threshold size for follow-up, the importance of the morphologic features of nodules, accurate nodule measurements, recognition of subsolid components, understanding interval growth or change in nodule morphology, and knowledge of patient risk factors. The updated guidelines enable greater personal flexibility in the decision-making process and encourage individualized management of pulmonary nodules. These factors may introduce new challenges for radiologists, who previously used solely nodule size to make management recommendations. The authors describe eight scenarios that illustrate the challenges potentially encountered when applying the new guidelines to pulmonary nodule management.

14 Guideline ERS/EACTS statement on the management of malignant pleural effusions. 2018

Bibby, Anna C / Dorn, Patrick / Psallidas, Ioannis / Porcel, Jose M / Janssen, Julius / Froudarakis, Marios / Subotic, Dragan / Astoul, Phillippe / Licht, Peter / Schmid, Ralph / Scherpereel, Arnaud / Rahman, Najib M / Cardillo, Giuseppe / Maskell, Nick A. ·Academic Respiratory Unit, University of Bristol Medical School Translational Health Sciences, Bristol, UK. · North Bristol Lung Centre, North Bristol NHS Trust, Bristol, UK. · Division of Thoracic Surgery, University Hospital Bern, Bern, Switzerland. · Oxford Respiratory Trials Unit, University of Oxford, Oxford, UK. · Pleural Medicine Unit, Arnau de Vilanova University Hospital, IRB Lleida, Lleida, Spain. · Dept of Pulmonary Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands. · Dept of Respiratory Medicine, Medical School of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece. · Clinic for Thoracic Surgery, Clinical Center of Serbia, Belgrade, Serbia. · Dept of Thoracic Oncology, Pleural Diseases and Interventional Pulmonology, Hospital North Aix-Marseille University, Marseille, France. · Dept of Cardiothoracic Surgery, Odense University Hospital, Odense, Denmark. · Pulmonary and Thoracic Oncology Dept, Hospital of the University (CHU) of Lille, Lille, France. · Oxford Centre for Respiratory Medicine, University Hospitals, NHS Foundation Trust, Oxford, UK. · Dept of Thoracic Surgery, Carlo Forlanini Hospital, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy. · Task force chairperson. ·Eur Respir J · Pubmed #30054348.

ABSTRACT: Malignant pleural effusions (MPE) are a common pathology, treated by respiratory physicians and thoracic surgeons alike. In recent years, several well-designed randomised clinical trials have been published that have changed the landscape of MPE management. The European Respiratory Society (ERS) and the European Association for Cardio-Thoracic Surgery (EACTS) established a multidisciplinary collaboration of clinicians with expertise in the management of MPE with the aim of producing a comprehensive review of the scientific literature.Six areas of interest were identified, including the optimum management of symptomatic MPE, management of trapped lung in MPE, management of loculated MPE, prognostic factors in MPE, whether there is a role for oncological therapies prior to intervention for MPE and whether a histological diagnosis is always required in MPE.The literature revealed that talc pleurodesis and indwelling pleural catheters effectively manage the symptoms of MPE. There was limited evidence regarding the management of trapped lung or loculated MPE. The LENT score was identified as a validated tool for predicting survival in MPE, with Brims' prognostic score demonstrating utility in mesothelioma prognostication. There was no evidence to support the use of oncological therapies as an alternative to MPE drainage, and the literature supported the use of tissue biopsy as the gold standard for diagnosis and treatment planning.

15 Guideline Expert consensus on image-guided radiofrequency ablation of pulmonary tumors: 2018 edition. 2018

Liu, Bao-Dong / Ye, Xin / Fan, Wei-Jun / Li, Xiao-Guang / Feng, Wei-Jian / Lu, Qiang / Mao, Yu / Lin, Zheng-Yu / Li, Lu / Zhuang, Yi-Ping / Ni, Xu-Dong / Shen, Jia-Lin / Fu, Yi-Li / Han, Jian-Jun / Li, Chen-Rui / Liu, Chen / Yang, Wu-Wei / Su, Zhi-Yong / Wu, Zhi-Yuan / Liu, Lei. ·Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China. · Department of Oncology, Provincial Hospital of Shandong University, Jinan, China. · Imaging and Interventional Department, Sun Yat-sen University Cancer Center, Guangzhou, China. · Minimally Invasive Department of Cancer, Beijing Hospital, Beijing, China. · Department of Oncology, Fuxing Hospital, Capital Medical University, Beijing, China. · Department of Thoracic Surgery, Tangdu Hospital, Air Force Medical University, Xi'an, China. · Department of Thoracic Surgery, Hohhot No.1 Hospital of Inner Mongolia Autonomous Region, Hohhot, China. · Intervention Department, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China. · Department of Thoracic Surgery, The 306th Hospital of PLA, Beijing, China. · Minimally Invasive Intervention Department of Jiangsu Cancer Hospital, Nanjing, China. · Department of Thoracic Surgery, Shanghai Zhongshan Hospital, Shanghai, China. · Cancer Intervention Department, South Hospital of Shanghai Renji Hospital, Shanghai, China. · Department of Thoracic Surgery, Beijing Chao Yang Hospital Affiliated to Capital Medical University, Beijing, China. · Minimally Invasive Department of Shandong Cancer Hospital, Jinan, China. · Intervention Department, Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China. · Intervention Department, Cancer Hospital, Peking University, Beijing, China. · Minimally Invasive Department of Cancer, The 307th Hospital of PLA, Beijing, China. · Department of Thoracic Surgery, Affiliated Hospital of Chifeng University of Inner Mongolia Autonomous Region, Chifeng, China. · Radiation Intervention Department, Shanghai Ruijin Hospital, Shanghai, China. ·Thorac Cancer · Pubmed #30039918.

ABSTRACT: Lung cancer ranks first in incidence and mortality in China. Surgery is the primary method to cure cancer, but only 20-30% of patients are eligible for curative resection. In recent years, in addition to surgery, other local therapies have been developed for patients with numerous localized primary and metastatic pulmonary tumors, including stereotactic body radiation therapy and thermal ablative therapies through percutaneously inserted applicators. Percutaneous thermal ablation of pulmonary tumors is minimally invasive, conformal, repeatable, feasible, cheap, has a shorter recovery time, and offers reduced morbidity and mortality. Radiofrequency ablation (RFA), the most commonly used thermal ablation technique, has a reported 80-90% rate of complete ablation, with the best results obtained in tumors < 3 cm in diameter. Because the clinical efficacy of RFA of pulmonary tumors has not yet been determined, this clinical guideline describes the techniques used in the treatment of localized primary and metastatic pulmonary tumors in nonsurgical candidates, including mechanism of action, devices, indications, techniques, potential complications, clinical outcomes, post-ablation surveillance, and use in combination with other therapies. In the future, the role of RFA in the treatment of localized pulmonary tumors should ultimately be determined by evidence from prospective randomized controlled trials comparing sublobar resection or stereotactic body radiation therapy.

16 Guideline Guideline for the Initial Management of Small Cell Lung Cancer (Limited and Extensive Stage) and the Role of Thoracic Radiotherapy and First-line Chemotherapy. 2018

Sun, A / Durocher-Allen, L D / Ellis, P M / Ung, Y C / Goffin, J R / Ramchandar, K / Darling, G. ·Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada. Electronic address: ccopgi@mcmaster.ca. · Program in Evidence-Based Care, McMaster University, Hamilton, Ontario, Canada. · Medical Oncology, Juravinski Cancer Centre, Hamilton, Ontario, Canada; Department of Oncology, McMaster University, Hamilton, Ontario, Canada. · Radiation Oncology, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada. · Medical Oncology, Juravinski Cancer Centre, Hamilton, Ontario, Canada. · Radiation Oncology, Thunder Bay Regional Health Sciences Centre, Thunder Bay, Ontario, Canada. · Thoracic Surgery, Toronto General Hospital, Toronto, Ontario, Canada. ·Clin Oncol (R Coll Radiol) · Pubmed #30007803.

ABSTRACT: AIMS: We investigated the efficacy of adding radiotherapy to chemotherapy in patients with extensive stage small cell lung cancer (ES-SCLC) and the appropriate timing, dose and schedule of treatment for patients with ES-SCLC or limited stage SCLC (LS-SCLC). MATERIALS AND METHODS: The guideline was developed by Cancer Care Ontario's Program in Evidence-Based Care and by the Lung Cancer Disease Site Group through a systematic review of randomised controlled trials. KEY RECOMMENDATIONS: In patients with LS-SCLC (stage I, II and III), the addition of thoracic radiotherapy to standard chemotherapy is recommended. However, there is no clear evidence to inform definitive recommendations for optimal timing, sequential versus concurrent therapies and optimal dose or regimen. In patients with LS-SCLC, etoposide-cisplatin is the preferred regimen for adults who are being treated with combined modality therapy with curative intent. In patients with ES-SCLC (stage IV), there is insufficient evidence to recommend the addition of thoracic radiotherapy to standard chemotherapy as a standard practice for survival benefit; however, it could be considered on a case-by-case basis to reduce local recurrence. In patients with ES-SCLC, a platinum agent plus etoposide is the preferred regimen for adult patients who are being treated with combined modality therapy. Cisplatin and irinotecan represents an alternative treatment option to this, but is associated with increased rates of adverse events such as diarrhoea.

17 Guideline NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. 2018

Ettinger, David S / Aisner, Dara L / Wood, Douglas E / Akerley, Wallace / Bauman, Jessica / Chang, Joe Y / Chirieac, Lucian R / D'Amico, Thomas A / Dilling, Thomas J / Dobelbower, Michael / Govindan, Ramaswamy / Gubens, Matthew A / Hennon, Mark / Horn, Leora / Lackner, Rudy P / Lanuti, Michael / Leal, Ticiana A / Lilenbaum, Rogerio / Lin, Jules / Loo, Billy W / Martins, Renato / Otterson, Gregory A / Patel, Sandip P / Reckamp, Karen / Riely, Gregory J / Schild, Steven E / Shapiro, Theresa A / Stevenson, James / Swanson, Scott J / Tauer, Kurt / Yang, Stephen C / Gregory, Kristina / Hughes, Miranda. · ·J Natl Compr Canc Netw · Pubmed #30006423.

ABSTRACT: The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the targeted therapy and immunotherapy sections in the NCCN Guidelines. For the 2018 update, a new section on biomarkers was added.

18 Guideline None 2018

Marzo-Castillejo, Mercè / Vela-Vallespín, Carmen / Bellas-Beceiro, Begoña / Bartolomé-Moreno, Cruz / Melús-Palazón, Elena / Vilarrubí-Estrella, Mercè / Nuin-Villanueva, Marian. ·Especialista en Medicina Familiar y Comunitaria y especialista en Medicina Preventiva y Salud Pública, Unitat de Suport a la Recerca de Costa de Ponent, IDIAP Jordi Gol, Direcció d'Atenció Primària Costa de Ponent, Institut Català de la Salut, Barcelona. · Especialista en Medicina Familiar y Comunitaria, EAP Riu Nord i Riu Sud, Santa Coloma de Gramenet, SAP Barcelona Nord i Maresme-ICS, Unitat Docent Metropolitana Nord, Barcelona. · Especialista en Medicina Familiar y Comunitaria, Complejo Hospitalario Universitario de Canarias y Unidad Docente de Atención Familiar y Comunitaria La Laguna-Tenerife Norte, Servicio Canario de Salud, Santa Cruz de Tenerife. · Especialista en Medicina Familiar y Comunitaria, Centro de Salud Goya de Zaragoza y Unidad Docente de Medicina Familiar y Comunitaria Sector Zaragoza I, Servicio Aragonés de Salud, Zaragoza. · Especialista en Medicina Familiar y Comunitaria, Centro de Salud Actur Oeste, Zaragoza, y Unidad Docente de Medicina Familiar y Comunitaria Sector Zaragoza I, Servicio Aragonés de Salud, Zaragoza. · Especialista en Medicina Familiar y Comunitaria, Servicio de Gestión Clínica y Sistemas de Información, Dirección de Atención Primaria, Servicio Navarro de Salud, Pamplona. · Grupo de Prevención del Cáncer del PAPPS. ·Aten Primaria · Pubmed #29866358.

ABSTRACT: -- No abstract --

19 Guideline SEOM-SERAM-SEMNIM guidelines on the use of functional and molecular imaging techniques in advanced non-small-cell lung cancer. 2018

Fernández Pérez, G / Sánchez Escribano, R / García Vicente, A M / Luna Alcalá, A / Ceballos Viro, J / Delgado Bolton, R C / Vilanova Busquets, J C / Sánchez Rovira, P / Fierro Alanis, M P / García Figueiras, R / Alés Martínez, J E. ·Departamento de Radiología, Hospital Universitario Río Hortega, Valladolid, España. · Departamento de Oncología Médica, Hospital Universitario de Burgos, Burgos, España. · Departamento de Medicina Nuclear, Hospital General Universitario, Ciudad Real, España. · Clínica Las Nieves, Health Time, Jaén, España; Department of Radiology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, Ohio, Estados Unidos. Electronic address: aluna70@htime.org. · Unidad de Oncología Médica, Hospital Nuestra Señora de Sonsoles, Complejo Asistencial de Ávila, Ávila, España. · Departamento de Diagnóstico por Imagen (Radiología) y Medicina Nuclear, Hospital de San Pedro y (CIBIR), Universidad de La Rioja, Logroño, España. · Servicio de Radiología, Institut Català de la Salut (IDI), Girona, Clínica Girona, Girona, España. · Departamento de Oncología Médica, Hospital Universitario de Jaén, Jaén, España. · Departamento de Medicina Nuclear, Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, España. · Departamento de Radiología, Complexo Hospitalario Santiago de Compostela, Santiago de Compostela, España. ·Radiologia · Pubmed #29807678.

ABSTRACT: Imaging in oncology is an essential tool for patient management but its potential is being profoundly underutilized. Each of the techniques used in the diagnostic process also conveys functional information that can be relevant in treatment decision making. New imaging algorithms and techniques enhance our knowledge about the phenotype of the tumor and its potential response to different therapies. Functional imaging can be defined as the one that provides information beyond the purely morphological data, and include all the techniques that make it possible to measure specific physiological functions of the tumor, whereas molecular imaging would include techniques that allow us to measure metabolic changes. Functional and molecular techniques included in this document are based on multi-detector computed tomography (CT), 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET), magnetic resonance imaging (MRI), and hybrid equipments, integrating PET with CT (PET/CT) or MRI (PET-MRI). Lung cancer is one of the most frequent and deadly tumors although survival is increasing thanks to advances in diagnostic methods and new treatments. This increased survival poises challenges in terms of proper follow-up and definitions of response and progression, as exemplified by immune therapy-related pseudoprogression. In this consensus document, the use of functional and molecular imaging techniques will be addressed to exploit their current potential and explore future applications in the diagnosis, evaluation of response and detection of recurrence of advanced NSCLC.

20 Guideline Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. 2018

Wood, Douglas E / Kazerooni, Ella A / Baum, Scott L / Eapen, George A / Ettinger, David S / Hou, Lifang / Jackman, David M / Klippenstein, Donald / Kumar, Rohit / Lackner, Rudy P / Leard, Lorriana E / Lennes, Inga T / Leung, Ann N C / Makani, Samir S / Massion, Pierre P / Mazzone, Peter / Merritt, Robert E / Meyers, Bryan F / Midthun, David E / Pipavath, Sudhakar / Pratt, Christie / Reddy, Chakravarthy / Reid, Mary E / Rotter, Arnold J / Sachs, Peter B / Schabath, Matthew B / Schiebler, Mark L / Tong, Betty C / Travis, William D / Wei, Benjamin / Yang, Stephen C / Gregory, Kristina M / Hughes, Miranda. · ·J Natl Compr Canc Netw · Pubmed #29632061.

ABSTRACT: Lung cancer is the leading cause of cancer-related mortality in the United States and worldwide. Early detection of lung cancer is an important opportunity for decreasing mortality. Data support using low-dose computed tomography (LDCT) of the chest to screen select patients who are at high risk for lung cancer. Lung screening is covered under the Affordable Care Act for individuals with high-risk factors. The Centers for Medicare & Medicaid Services (CMS) covers annual screening LDCT for appropriate Medicare beneficiaries at high risk for lung cancer if they also receive counseling and participate in shared decision-making before screening. The complete version of the NCCN Guidelines for Lung Cancer Screening provides recommendations for initial and subsequent LDCT screening and provides more detail about LDCT screening. This manuscript focuses on identifying patients at high risk for lung cancer who are candidates for LDCT of the chest and on evaluating initial screening findings.

21 Guideline ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer. 2018

Nestle, Ursula / De Ruysscher, Dirk / Ricardi, Umberto / Geets, Xavier / Belderbos, Jose / Pöttgen, Christoph / Dziadiuszko, Rafal / Peeters, Stephanie / Lievens, Yolande / Hurkmans, Coen / Slotman, Ben / Ramella, Sara / Faivre-Finn, Corinne / McDonald, Fiona / Manapov, Farkhad / Putora, Paul Martin / LePéchoux, Cécile / Van Houtte, Paul. ·Department of Radiation Oncology, Kliniken Maria Hilf, Moenchengladbach, Germany; Department of Radiation Oncology, University Hospital Freiburg, Germany. Electronic address: ursula.nestle@mariahilf.de. · Maastricht University Medical Center, Department of Radiation Oncology (Maastro clinic), GROW School for Oncology and Developmental Biology, The Netherlands; KU Leuven, Radiation Oncology, Belgium. · Department of Oncology, University of Turin, Italy. · Department of Radiation Oncology, Cliniques universitaires Saint-Luc, MIRO - IREC Lab, UCL, Belgium. · Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. · Department of Radiation Oncology, West German Tumor Centre, University of Duisburg-Essen Medical School, Germany. · Department of Oncology and Radiotherapy, Medical University of Gdańsk, Poland. · Maastricht University Medical Center, Department of Radiation Oncology (Maastro clinic), GROW School for Oncology and Developmental Biology, The Netherlands. · Department of Radiation Oncology, Ghent University Hospital, Belgium. · Catharina Hospital, Department of Radiation Oncology, Eindhoven, The Netherlands. · Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands. · Department of Radiation Oncology, Campus Bio-Medico University, Rome, Italy. · University of Manchester & The Christie NHS Foundation Trust, Manchester, UK. · Department of Radiotherapy, The Royal Marsden NHS Foundation Trust, London, UK. · Department of Radiation Oncology, University Hospital, LMU Munich, Germany. · Department of Radiation Oncology, Kantonsspital St. Gallen, Switzerland; Medical Faculty, University of Bern, Switzerland. · Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France. · Department Radiation Oncology, Institut Bordet, Université Libre Bruxelles, Belgium. ·Radiother Oncol · Pubmed #29605476.

ABSTRACT: Radiotherapy (RT) plays a major role in the curative treatment of locally advanced non-small cell lung cancer (NSCLC). Therefore, the ACROP committee was asked by the ESTRO to provide recommendations on target volume delineation for standard clinical scenarios in definitive (chemo)radiotherapy (RT) and adjuvant RT for locally advanced NSCLC. The guidelines given here are a result of the evaluation of a structured questionnaire followed by a consensus discussion, voting and writing procedure within the committee. Hence, we provide advice for methods and time-points of diagnostics and imaging before the start of treatment planning and for the mandatory and optional imaging to be used for planning itself. Concerning target volumes, recommendations are given for GTV delineation of primary tumour and lymph nodes followed by issues related to the delineation of CTVs for definitive and adjuvant radiotherapy. In the context of PTV delineation, recommendations about the management of geometric uncertainties and target motion are given. We further provide our opinions on normal tissue delineation and organisational and responsibility questions in the process of target volume delineation. This guideline intends to contribute to the standardisation and optimisation of the process of RT treatment planning for clinical practice and prospective studies.

22 Guideline Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement Summary of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. 2018

Kalemkerian, Gregory P / Narula, Navneet / Kennedy, Erin B. ·University of Michigan, Ann Arbor, MI; Weill Cornell Medicine, New York, NY; and American Society of Clinical Oncology, Alexandria, VA. ·J Oncol Pract · Pubmed #29589987.

ABSTRACT: -- No abstract --

23 Guideline [PD-L1 testing in non-small cell lung carcinoma: Guidelines from the PATTERN group of thoracic pathologists]. 2018

Lantuejoul, Sylvie / Adam, Julien / Girard, Nicolas / Duruisseaux, Mickael / Mansuet-Lupo, Audrey / Cazes, Aurélie / Rouquette, Isabelle / Gibault, Laure / Garcia, Stéphane / Antoine, Martine / Vignaud, Jean Michael / Galateau-Sallé, Françoise / Sagan, Christine / Badoual, Cécile / Penault-Llorca, Frédérique / Damotte, Diane / Anonymous7670940. ·Département de biopathologie et département de recherche translationnelle et d'innovations, centre Léon-Bérard UNICANCER, 28, rue Laennec, 69008 Lyon, France; Inserm U1209/CNRS 5309, Grenoble-Alpes université, Institute for Advanced Biosciences, 38700 La Tronche, France. Electronic address: sylvie.lantuejoul@lyon.unicancer.fr. · Département de biologie et pathologie médicales, Gustave-Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif, France; Inserm U981, Gustave-Roussy, 94805 Villejuif, France. · Institut du thorax Curie-Montsouris, institut Curie, 75005 Paris, France; Université Claude-Bernard Lyon 1, université de Lyon, 69622 Villeurbanne, France. · Inserm 1052, CNRS 5286, centre de recherche en cancérologie de Lyon, institut de cancérologie des Hospices Civiles de Lyon (IC-HCL), service de pneumologie, hôpital Louis-Pradel, 69008 Lyon, France. · Département de pathologie, hôpital Cochin, université Paris Descartes, Assistance publique-hôpitaux de Paris, 74014 Paris, France. · Inserm UMR1152, département de pathologie, hôpital Bichat, université Paris Diderot, 75018 Paris, France. · Département de pathologie, IUCT Oncopôle, CHU de Toulouse, 31059 Toulouse, France. · Département de pathologie, hôpital européen Georges-Pompidou, Assistance publique-hôpitaux de Paris, 75015 Paris, France; Inserm UMR-S970, Paris centre de recherche cardiovasculaire, Georges-Pompidou European Hospital, 75015 Paris, France. · Département de Pathologie, hôpital Nord, Assistance publique-hôpitaux de Marseille, Aix-Marseille Université, CRCM, 13015 Marseille, France. · Service d'anatomie pathologique, hôpital Tenon AP-HP, 75020 Paris, France; UPMC université Paris 06, GRC n(o) 04, Theranoscan, 75252 Paris, France. · Département de pathologie, CHRU de Nancy, 54035 Nancy, France; Inserm 1256, université de Lorraine, 54505 Vandœuvre-lès-Nancy, France. · Centre National Référent MESOPATH, Base Clinicobiologique nationale MESOBANK, Registre multicentrique MESONAT centre Leon-Bérard, département de biopathologie, 69008 Lyon, France. · Inserm U1087, institut du Thorax, service d'anatomie et cytologique pathologiques, hôpital Hotel-Dieu, CHU de Nantes, 44093 Nantes, France. · UMR Inserm 1240 IMoST, Centre Jean-Perrin, département de pathologie, université Clermont-Auvergne, 63011 Clermont-Ferrand, France. ·Ann Pathol · Pubmed #29571563.

ABSTRACT: Lung cancer is the leading cause of cancer death in France with low response rates to conventional chemotherapy. Nevertheless, new therapies have emerged recently, among which PD1 immune checkpoint inhibitors (ICI), such as nivolumab (OPDIVO

24 Guideline Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline Summary. 2018

Kindler, Hedy L / Ismaila, Nofisat / Hassan, Raffit. ·The University of Chicago, Chicago, IL; American Society of Clinical Oncology, Alexandria VA; and National Cancer Institute, Bethesda, MD. ·J Oncol Pract · Pubmed #29517955.

ABSTRACT: -- No abstract --

25 Guideline Introducing the new BTS guideline: the investigation and management of pleural malignant mesothelioma. 2018

Woolhouse, Ian / Maskell, Nick A. ·Department of Respiratory Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. · Academic Respiratory Unit, Southmead Hospital, University of Bristol, Bristol, UK. ·Thorax · Pubmed #29444989.

ABSTRACT: -- No abstract --

Next